Morgan Stanley Raises Genmab Price Target to $57 From $42
Morgan Stanley maintained its Equal-Weight rating on Genmab and raised its price target to $57 from $42.
Related stories
Banco Santander Chile Reports Quarterly Results
The report covers the quarter ended September 30. Its body contains no specific results.
M impact | EQUITY | Oct 31, 2026, 05:01 PM UTC
Wilmar Reports $22.5 Million in FY2025 Fertilizer and Diesel Sales
Wilmar said sales to six companies named by the NEA totaled USD 22.5 million in FY2025.
M impact | EQUITY | Oct 31, 2026, 03:58 PM UTC
Pursuit Makes AI Assistant Default Platform Home Screen
Pursuit says its assistant helps sales representatives find potential leads, identify likely agency buyers and manage contract renewals. The platform is also optimized for mobile w
M impact | EQUITY | Oct 31, 2026, 01:04 PM UTC
AstraZeneca Reports Q3 Revenue of $16.21 Billion; Oncology Rises 17%
The headline also reports a decline for Farxiga and an Etcamah miss; it does not specify what Etcamah missed.
M impact | EQUITY | Oct 31, 2026, 08:04 AM UTC
BP Posts Record Q3 Profit, Cuts Net Debt to $13.9 Billion
M impact | EQUITY | Oct 31, 2026, 08:01 AM UTC
TTE Plans Buybacks, Sets Gas Target and 50% OPL257 Interest
The headline says TTE plans buybacks, targets an additional 1 Bcf/d of gas and has a 50% interest in OPL257; no further details are provided.
M impact | EQUITY | Oct 31, 2026, 08:01 AM UTC